Key MessagesThis study presents the epidemiological and clinical characteristics of a patient cohort of 671 confirmed COVID-19 cases in Henan province, the largest province in terms of population size and ranked as the third most severely affected province in China.To the best of our knowledge, our study is the largest report of COVID-19 clinical characteristics in China outside Wuhan at the provincial level that offers direct evidence on SARS-CoV-2 transmission manifestations.Insights gained from this study could guide clinical practice on COVID-19 diagnosis and pathogen transmission control at both governmental and individual levels.

Introduction
============

Ever since the outbreak of novel coronavirus disease (COVID-19) infection in Wuhan, China, this disease has rapidly spread from Wuhan to other areas in China and globally. It has now affected \>200 countries, with the epicenter shifted from Asia to Europe and North America. The pathological agent, severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), was identified on 3 January 2020, and confirmed (through full genome sequencing and phylogenic analysis) as a distinct clade from the beta-coronaviruses that had caused SARS and Middle East respiratory syndrome (MERS) in 2003 and 2012, respectively.[@OP-B1] Bats were considered to be the original carriers of SARS-CoV-2, and pangolins were recently identified as the intermediate host. Human-to-human transmission is evident.[@OP-B2] Many studies have reported the epidemiological and clinical features of COVID-19 in Wuhan,[@OP-B1] whereas relatively little has been reported on COVID-19 outside Wuhan in China, except for a report on 13 confirmed cases admitted to hospitals in Beijing.[@OP-B5]

Here, we present a case series that encompasses 671 patients with COVID-19 in Henan province, which has the largest population (\>10 million permanent residents) and was ranked as the third most affected region in China. The global picture on the COVID-19 situation in China was recently published, covering 31 provinces and including 1099 clinical cases.[@OP-B4] Yet the present study is, to our knowledge, the largest report on COVID-19 at the provincial level outside Wuhan in China to study the manifestations of SARS-CoV-2 in its transmitted region.

Methods
=======

Data collection
---------------

Data on all consecutive patients with confirmed COVID-19 infection in Henan province from 23 January to 5 February 2020 were collected from 279 hospitals. Oral consent was obtained from patients. All 671 patients with COVID-19 enrolled in this study were diagnosed according to World Health Organization interim guidance.[@OP-B6] Clinical outcomes (i.e. discharges, mortality) and disease severity were monitored up to 5 February 2020, the final date of follow-up.

The medical records of patients were analysed by the research team of the Center for Disease Control (CDC) of Henan Province. Epidemiological, clinical, laboratory and radiological characteristics and outcomes data were obtained with data collection forms from electronic medical records. Information recorded included demographic data, medical history, exposure history, underlying comorbidities, laboratory findings, X-rays and chest computed tomography (CT) scans. The date of disease onset was defined as the day when the first symptoms were noticed. Laboratory test values, X-rays and chest CT scans were collected.

Cardiovascular diseases are a group of disorders of the heart and blood vessels, including cerebrovascular disease and coronary heart disease, peripheral arterial disease and rheumatic heart disease. Hypertension was defined according to the American Heart Association expert consensus.[@OP-B7] Respiratory diseases were defined as many disorders affecting the lungs, including asthma, chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease and tuberculosis. Diabetes was defined according to the American Diabetes Association's diagnostic criteria.[@OP-B8]

Laboratory testing
------------------

Throat or nose swab samples were collected for extracting SARS-CoV-2 RNA from patients suspected of having SARS-CoV-2 infection. After sample collection, total RNA was extracted within 2 h using a respiratory sample RNA isolation kit (Shanghai bio-germ Medical Technology Co Ltd, Catlog number: ZC-HX-201--2) and was tested using a SARS-CoV-2 nucleic acid real-time reverse transcription polymerase chain reaction (RT-PCR) detection kit, following the manufacturer's protocol (Shanghai bio-germ Medical Technology Co Ltd) in biosafety level 2 facilities at the Henan (provincial) CDC. The primers and sequences targeting open reading frame (ORF) 1ab were: forward primer CCCTGTGGGTTTTACACTTAA, reverse primer ACGATTGTGCATCAGCTGA, and probe 5′-FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3′. The primers and sequences targeting nucleocapsid protein (N) were: forward primer GGGGAACTTCTCCTGCTAGAAT, reverse primer CAGACATTTTGCTCTCAAGCTG and probe 5′-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3′. Conditions for the amplifications were 50°C for 10 min, 95°C for 5 min, followed by 40 cycles of 95°C for 10 s and 55°C for 40 s. A cycle threshold value (Ct-value) \<37 was defined as a positive test, and a Ct-value ≥40 was defined as a negative test. A medium load, defined as a Ct-value of 37 to \<40, required confirmation by retesting. If two targets (ORF 1a or 1 b, nucleocapsid protein) tested positive by specific real-time RT-PCR in the initial or second test, the case would be considered to be laboratory-confirmed. These diagnostic criteria were based on the recommendation of the National Institute for Viral Disease Control and Prevention (China) (<http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html>).

Statistical analysis
--------------------

Continuous variables are described using mean, standard deviation (SD), median and interquartile range (IQR) values, and categorical variables as frequency and percentage. Normality testing was performed using the Shapiro--Wilk test. Means for continuous variables were compared using independent group tests when the data were normally distributed; otherwise, Mann--Whitney *U* test and Kruskal--Wallis H test were used (adjusted by Bonferroni correction). Proportions for categorical variables were compared using the χ^2^ test or Fisher exact test. The correlation of the two variables was compared using the Spearman rank correlation. The influencing variables for the severity and non-severity of COVID-19 were analysed using a logistic regression model. All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences) version 23.0 software (SPSS Inc).

Ethics approval
===============

This study was approved by the ethics commissions of the Henan Center for Disease Control and Prevention, with a waiver of written consent.

Results
=======

The mean and median ages of the patients were 43 ± 15.09 and 44 (31--53) years, respectively; 56.2% were male and 22.4% (151) had coexisting medical disorders or a previous record. Seventy patients (10.4%) had cardiovascular diseases, of whom 60 (85.7%) had hypertension, 12 (1.8%) had diabetes, 17 (2.5%) had respiratory diseases, 19 (2.8%) had both cardiovascular disease and diabetes, and two (0.3%) had both respiratory disease and diabetes. Thirty-three patients (4.9%) had other complications, such as hepatitis, nephrosis, gastritis and trauma ([Table 1](#dyaa081-T1){ref-type="table"}). The distribution of disease severity did not follow a normal distribution (Shapiro--Wilk statistic = 0.751, *P *=* *3.05 × 10^--30^), wherein 14 patients (2.1%) were symptom-free, 163 (24.3%) had light symptoms, 420 (62.6%) were normal, 66 (9.8%) had severe disease and six patients (0.9%) were at the terminal stage ([Table 1](#dyaa081-T1){ref-type="table"}). Sixteen patients (2.4%) were admitted to the intensive care unit (ICU). A total of 615 patients (91.7%) remained in hospital, 54 patients (8%) were discharged and two patients (0.3%) had died by February 5 ([Table 1](#dyaa081-T1){ref-type="table"}). The mortality rate was 0.3%; much lower than that reported for Wuhan (4.3%).[@OP-B3]

###### 

Baseline characteristics, contact histories, diagnosis and clinical outcomes of 671 patients with COVID-19 in Henan Province (23 January to 5 February 2020)

  Clinical characteristics                           Statistics[^a^](#tblfn1){ref-type="table-fn"}
  ------------------------------------------------- -----------------------------------------------
  Age (years)                                       
   Mean (SD)                                                           43±15.09
   Median (IQR)                                                       44 (31--53)
   Range                                                                0.5--88
  Sex                                               
   Male                                                               377 (56.2%)
   Female                                                             294 (43.8%)
  Coexisting disorder                               
   Cardiovascular diseases                                            70 (10.4%)
   Hypertension                                                           60
   Diabetes                                                            12 (1.8%)
   Respiratory diseases                                                17 (2.5%)
   Cardiovascular diseases and diabetes                                19 (2.8%)
   Respiratory diseases and diabetes                                   2 (0.3%)
   Other                                                               33 (4.9%)
   None                                                               518 (77.2%)
  Disease severity                                  
   Symptom-free                                                        14 (2.1%)
   Light                                                              163 (24.3%)
   Normal                                                             420 (62.6%)
   Severe                                                              66 (9.8%)
   Terminal                                                            6 (0.9%)
   NA^b^                                                               2 (0.3%)
  Admission to ICU                                  
   Yes                                                                 16 (2.4%)
   No                                                                 653 (97.3%)
   NA                                                                  2 (0.3%)
  Clinical outcome                                  
   Remained in hospital                                               615 (91.7%)
   Discharged                                                          54 (8.0%)
   Died                                                                2 (0.3%)
  Animal--human transmission source contact         
   Direct contact                                                     330 (49.2%)
    Live                                                              273 (82.7%)
    Visit                                                             57 (17.3%)
   Indirect contact                                                   306 (45.6%)
    Contact with confirmed cases                    
    Yes                                                               150 (22.4%)
    No                                                                516 (76.9%)
    NA                                                                 5 (0.7%)
   Contact with suspected cases                     
    Yes                                                               131 (19.5%)
    No                                                                461 (68.7%)
    NA                                                                79 (11.8%)
   Contact with individuals who had been to Wuhan   
    Yes                                                               253 (37.7%)
    No                                                                339 (50.5%)
    NA                                                                79 (11.8%)
   Close to cluster outbreak                        
    Yes                                                               132 (19.7%)
    No                                                                492 (73.3%)
    NA                                                                 47 (7.0%)
   Visited hospital                                 
    Yes                                                               323 (48.1%)
    No                                                                269 (40.1%)
    NA                                                                79 (11.8%)
   Visited wet market                               
    Yes                                                               119 (17.7%)
    No                                                                534 (79.6%)
    NA                                                                 18 (2.7%)
   No contact                                                          33 (4.9%)
  NA                                                                   2 (0.3%)
  Days from illness onset to diagnosis              
   Mean (SD)                                                            5.6±3.7
   Range                                                                 0--32
  X-ray with pneumonia features                     
   Yes                                                                83 (12.4%)
   No                                                                 156 (23.2%)
   Untested                                                           353 (52.6%)
   NA                                                                 79 (11.8%)
  CT with pneumonia features                        
   Yes                                                                539 (80.3%)
   No                                                                  23 (3.4%)
   Untested                                                            30 (4.5%)
   NA                                                                 79 (11.8%)
  Blood routine test                                
   Leucocytes (×10^9^/L; normal range 3.5--9.5)                    4.98 (3.83--6.42)
    Increased                                                          30 (4.5%)
    Normal                                                            473 (70.5%)
    Decreased                                                         103 (15.4%)
    NA                                                                 65 (9.7%)
   Lymphocytes (×10^9^/L; normal range 1.1--3.2)                   1.18 (0.86--1.74)
    Increased                                                          42 (6.3%)
    Normal                                                            292 (43.5%)
    Decreased                                                         262 (39.0%)
    NA                                                                75 (11.2%)
   Lymphocyte percentage (normal range 20--50%)                  24.50 (16.25--31.90)
    Increased                                                          23 (3.4%)
    Normal                                                            356 (53.1%)
    Decreased                                                         218 (32.5%)
    NA                                                                74 (11.0%)
   Neutrophil percentage (normal range 50--70%)                  66.10 (56.50--74.85)
    Increased                                                         235 (35.0%)
    Normal                                                            278 (41.4%)
    Decreased                                                         80 (11.9%)
    NA                                                                78 (11.6%)

Statistics include one of the following: mean ± SD, range, number, number (percentage), median (IQR), as indicated; ^b^NA, not applicable.

In this case series, 330 patients had ever lived in (40.7%) or visited (8.5%) Wuhan, accounting for up to 49.2% of the cohort. Among patients without a direct association with Wuhan, 150 (22.4%) had contact with confirmed cases, 131 (19.5%) had contact with suspected cases, 253 (37.7%) had contact with individuals who had ever lived in or visited Wuhan, 132 (19.7%) were close to one or several cluster outbreaks, 323 (48.1%) (including 17 medical workers) had visited a hospital and 119 (17.7%) had been to a wet market ([Table 1](#dyaa081-T1){ref-type="table"}). There were 33 patients (4.9%) with no traceable contact history, according to the design of our questionnaire ([Table 1](#dyaa081-T1){ref-type="table"}).

The frequency of COVID-19 infection by occupation in patients in Henan province was highest in farmers (89, 13.3%), followed by workmen (81, 12.1%) ([Figure 1A](#dyaa081-F1){ref-type="fig"}). Among the 33 patients without a known transmission source, the same trend was seen (i.e. farmers: 7, 21.2%; followed by workmen: 5, 15.2%) ([Figure 1B](#dyaa081-F1){ref-type="fig"}). There were 17 patients who were medical workers, 7 were children (aged ≤8 years) and 3 were pregnant.

![Occupation distribution of confirmed COVID-19 cases. (A) All 669 COVID-19 patients. (B) 33 cases with unknown transmission source. Two cases without available information on occupation were excluded.](dyaa081f1){#dyaa081-F1}

The average time from illness onset to diagnosis was 5.6 days, ranging from 0 to 32 days. Among the 671 individuals at admission, 239 received X-rays, with 83 showing clear pneumonia features (34.7%); 562 had chest CT scans, with 539 exhibiting pneumonia characteristics (95.9%); and 606 patients received routine blood tests, with 606, 596, 597 and 593 patients having available information on leucocyte count, lymphocyte count, lymphocyte percentage and neutrophil percentage, respectively, and 598 having available information on all routine blood test indexes ([Table 1](#dyaa081-T1){ref-type="table"}). The median leucocyte count was 4.98 × 10^9^/L (IQR, 3.83--6.42), lymphocyte count was 1.18 × 10^9^/L (IQR, 0.86--1.74), lymphocyte percentage was 24.5% (IQR, 16.25--31.9) and neutrophil percentage was 66.1% (IQR, 56.5--74.85) ([Table 1](#dyaa081-T1){ref-type="table"}).

By removing patients without COVID-19 severity information or symptoms from the analysis, we collected data on 655 patients to study the sensitivity and accuracy of traditional pneumonia diagnostic approaches. Among X-ray, CT scan and routine blood test (including leucocyte and lymphocyte counts, and lymphocyte and neutrophil percentages), lymphocyte percentage played a significant role in differentiating patients' COVID-19 infection severity (χ^2^ = 6.71, *P *=* *0.035, [Table 2](#dyaa081-T2){ref-type="table"}), followed by neutrophil percentage (χ^2^ = 4.943, *P *=* *0.084, [Table 2](#dyaa081-T2){ref-type="table"}). In general, lymphocyte percentage and neutrophil percentage decreased and increased, respectively, with more severe disease. The IQR of lymphocyte percentage largely overlapped with the lower 50% percentile of the range typically considered healthy (i.e. COVID-19, 13.75--32.91% vs healthy, 20--50%). The IQR of neutrophil percentage among infected individuals spanned and encompassed the normal range (i.e. COVID-19, 55.48--81.8% vs healthy, 50--70%). The IQR of leucocyte count fell in the normal range. Lymphocyte count was, in general, decreased in COVID-19 infected individuals, but its IQR overlapped with the normal range (i.e. COVID-19, 0.84--1.83 × 10^9^/L vs healthy, 1.1--3.2  × 10^9^/L). CT scans showed a higher detection rate than did X-ray (96 vs 35%) ([Table 2](#dyaa081-T2){ref-type="table"}). Thirteen cases showing scattered opacities on X-ray were not detected from CT scans, and 147 cases showing bilateral ground glass opacities on CT scans did not show typical pneumonia features on X-ray. There were 5 cases undetected from either X-ray or CT scans. These 5 patients were all female, except for a 16-year-old boy, and all had light or normal severity of infection.

###### 

Comparisons of canonical pneumonia detection methods in the accuracy of COVID-19 severity diagnosis

  Diagnostic approach                                   Parameter              Number          Light                  Normal                 Severe          χ^2^     *P*
  ----------------------------------------------------- --------------------- -------- ---------------------- ---------------------- ---------------------- ------- -------
  X-ray                                                                                         163                    420                     72                   
   Yes                                                  Number (percentage)      82          22 (31.4%)             47 (33.8%)             13 (46.4%)        2.08    0.353
   No                                                   Number (percentage)     155          48 (68.6%)             92 (66.2%)             15 (53.6%)               
   Untested/NA[^a^](#tblfn2){ref-type="table-fn"}       Removed                 418              93                    281                     44                   
  CT                                                                                                                                                                
   Yes                                                  Number (percentage)     535         150 (97.4%)            333 (94.9%)             52 (100%)         4.166   0.125
   No                                                   Number (percentage)      22           4 (2.6%)              18 (5.1%)                  0                    
   Untested/NA                                          Removed                  98              9                      69                     20                   
  Routine blood test                                                                                                                                                
   Leucocyte count (×10^9^/L, normal range 3.5--9.5)    Median (IQR)            606      5.19 (3.61--6.66)      4.79 (3.86--6.13)      5.52 (4.03--6.79)     3.334   0.189
                                                        Range                                1.56--16.5            1.11--16.07             2.3--15.48               
   Lymphocyte count (×10^9^/L, normal range 1.1--3.2)   Median (IQR)            596      1.22 (0.86--1.83)      1.18 (0.86--1.74)      1.16 (0.84--1.63)     1.051   0.591
                                                        Range                                0.02--70.3              0.07--77               0.36--78                
   Lymphocyte percentage (normal range 20--50%)         Median (IQR)            597     26.25 (16.83--32.91)   24.75 (16.70--31.70)   18.70 (13.75--28.21)   6.71    0.035
                                                        Range                                0.4--85.1              0.2--83.5              0.2--80.28               
   Neutrophil percentage (normal range 50--70%)         Median (IQR)            593     64.60 (55.48--74.50)   66.01 (56.70--74.40)   71.70 (57.40--81.80)   4.943   0.084
                                                        Range                                1.45-91.7              1.1--90.9             0.74--93.04               

NA, Not applicable.

The number of days from illness onset to diagnosis was associated with COVID-19 infection severity \[correlation: 0.186, 95% confidence interval (CI): 0.110--0.259, *P *=* *2 × 10^--6^, [Table 3](#dyaa081-T3){ref-type="table"}\], wherein patients with severe disease, in general, took a longer time from illness onset to diagnosis ([Table 3](#dyaa081-T3){ref-type="table"}). The number of days from illness onset to diagnosis was also positively correlated with comorbidities (correlation: 0.089, 95% CI: 0.014--0.171, *P *=* *0.022) and age (correlation: 0.086, 95% CI: 0.010--0.163, *P *=* *0.027) and was marginally associated with sex ([Table 3](#dyaa081-T3){ref-type="table"}). Female patients experienced slightly fewer days from illness onset to diagnosis than male patients, with significance (correlation: --0.075, 95% CI: --0.149 to --0.001, *P *=* *0.055, [Table 3](#dyaa081-T3){ref-type="table"}).

###### 

Spearman correlation of days from illness onset to diagnosis with comorbidities, age and COVID-19 severity

                 Comorbidities[^a^](#tblfn3){ref-type="table-fn"}                     Age                            Sex                       COVID-19 severity
  ------------- -------------------------------------------------- ----------------------------------------- -------------------- -------------------------------------------
  Correlation        0.089[\*](#tblfn4){ref-type="table-fn"}        0.086[\*](#tblfn4){ref-type="table-fn"}        --0.075         0.186[\*\*](#tblfn5){ref-type="table-fn"}
  95% CI                          0.014 to 0.171                                0.010 to 0.163                --0.149 to --0.001                0.110 to 0.259
  *P*                                 0.022                                          0.027                          0.055                         2 × 10^--6^

Comorbidities are classified as cardiovascular diseases including hypertension (CCH), non-CCH and no disorder.

*P *\<* *0.05 (two-tails);

*P *\<* *0.01 (two-tails).

By including all epidemiological, clinical and laboratory factors, as well as contact histories, in a univariate logistic regression model explaining patient severity, we identified five factors that potentially influenced COVID-19 severity. These factors are age, contact with confirmed cases, days from illness onset to diagnosis, lymphocyte percentage and neutrophil percentage. By fitting these into the multivariate logistic regression model, age \[*P *=* *0.003, odds ratio (OR) = 1.026, 95% CI: 1.009--1.043\], contact with confirmed cases (*P *=* *0.039, OR = 0.456, 95% CI: 0.213--0.976), days from illness onset to diagnosis (*P *=* *0.004, OR = 1.065, 95% CI: 1.003--1.132), lymphocyte percentage (*P *=* *0.015, OR = 0.98, 95% CI: 0.957--1.003) and neutrophil percentage (*P *=* *0.033, OR = 1.004, 95% CI: 0.989--1.019) were closely associated with disease severity ([Table 4](#dyaa081-T4){ref-type="table"}). By analysing variables identified from the multivariate logistic regression model and using univariate models separately, age (*P *=* *0.002, OR = 1.026, 95% CI: 1.009--1.043), contact with confirmed cases (*P *=* *0.043, OR = 0.456, 95% CI: 0.213--0.976), days from illness onset to diagnosis (*P *=* *0.04, OR = 1.065, 95% CI: 1.003--1.132) and lymphocyte percentage (*P *=* *0.009, OR = 0.517, 95% CI: 0.315--0.848) were identified as prognostic of disease severity ([Table 5](#dyaa081-T5){ref-type="table"}).

###### 

Statistics of the multivariate logistic regression model for severe versus non-severe COVID-19 as stratified by epidemiological, clinical and laboratory factors, as well as contact histories of 655 patients with COVID-19 in Henan Province (23 January to 5 February 2020)

  Clinical characteristics                               Non-severe (*n* = 583)    Severe (*n* = 72)     *z*/χ^2a^    *P*         OR (95%CI)
  ----------------------------------------------------- ------------------------ ---------------------- ----------- ------- ----------------------
  Age (years)                                                                                                               
   Median (IQR)                                               43 (31--52)            48.5 (34--58)        --3.020    0.003   1.026 (1.009--1.043)
  Sex                                                                                                                       
   Male                                                       324 (55.6%)              43 (59.7%)          0.447     0.504   0.844 (0.512--1.389)
   Female                                                     259 (44.4%)              29 (40.3%)                           
  Coexisting disorder                                                                                                       
   Cardiovascular diseases                                         62                      8               0.015     0.902   0.809 (0.306--2.142)
   Hypertension                                                    55                      5               0.477     0.490   0.494 (0.168--1.451)
   Diabetes                                                        11                      0               0.475     0.491           ---
   Respiratory diseases                                            15                      2              \<0.001    1.000   0.910 (0.191--4.333)
   Cardiovascular diseases and diabetes                            15                      4               1.104     0.293   2.062 (0.605--7.035)
   Respiratory diseases and diabetes                               2                       0              \<0.001    1.000           ---
   Other                                                           26                      5               0.413     0.520   1.442 (0.476-4.366)
  Animal/human transmission source contact                                                                                  
   Direct                                                         284                      39              0.414     0.520   1.062 (0.695--1.622)
    Live                                                      238 (83.8%)              29 (74.4%)          2.134     0.144   1.738 (1.152--2.622)
    Visit                                                      46 (16.2%)              10 (25.6%)                           
   Indirect                                                       266                      31                               
    Contact with confirmed cases                                                                                            
     Yes                                                      128 (22.1%)              8 (11.4%)           4.274     0.039   0.456 (0.213--0.976)
     No                                                       452 (77.9%)              62 (88.6%)                           
     NA                                                            3                       2                                
   Contact with suspected cases                                                                                             
    Yes                                                       112 (21.5%)              9 (16.1%)           0.886     0.347   0.701 (0.333--1.474)
    No                                                        410 (78.5%)              47 (83.9%)                           
    NA                                                             61                      16                               
   Contact with individuals who had been to Wuhan                                                                           
    Yes                                                       221 (42.3%)              21 (37.5%)          0.486     0.486   0.817 (0.463--1.442)
    No                                                        301 (57.7%)              35 (62.5%)                           
    NA                                                             61                      16                               
   Close to cluster outbreak                                                                                                
    Yes                                                       104 (19.2%)              14 (20.9%)          0.111     0.739   1.112 (0.595--2.082)
    No                                                        438 (80.8%)              53 (79.1%)                           
    NA                                                             41                      5                                
   Visited hospital                                                                                                         
    Yes                                                       285 (54.6%)              38 (67.9%)          3.607     0.058   1.756 (0.976--3.157)
    No                                                        237 (45.4%)              18 (32.1%)                           
    NA                                                             61                      16                               
   Visited wet market                                                                                                       
    Yes                                                       102 (17.9%)              15 (22.1%)          0.692     0.406   1.296 (0.703--2.389)
    No                                                        467 (82.1%)              53 (77.9%)                           
    NA                                                             14                      4                                
   No contact                                                      32                      1                                
    NA                                                             1                       1                                
  Days from illness onset to diagnosis                                                                                      
    Median (IQR)                                                5 (3--8)                6 (4--9)          --2.896    0.004   1.065 (1.003--1.132)
  X-ray with pneumonia features                                                                                             
    Yes                                                        69 (33.0%)              13 (46.4%)          1.964     0.161   1.758 (0.793--3.901)
    No                                                        140 (67.0%)              15 (53.6%)                           
  CT with pneumonia features                                                                                                
    Yes                                                       483 (96.7%)              52 (92.9%)          0.367     0.544           ---
    No                                                         22 (4.2%)                4 (7.1%)                            
  Blood routine test                                                                                                        
   Leucocyte count (×10^9^/L; normal range 3.5--9.5)       4.83 (3.82--6.35)       5.52 (4.03--6.79)      --1.656    0.098   1.103 (0.996--1.222)
    Increased                                                  24 (4.5%)                6 (9.4%)           2.883     0.237   1.370 (0.760--2.469)
    Normal                                                    420 (78.5%)              48 (75.0%)                           
    Decreased                                                  91 (17.0%)              10 (15.6%)                           
   Lymphocyte count (×10^9^/L; normal range 1.1--3.2)      1.20 (0.86--1.75)       1.16 (0.84--1.63)      --0.941    0.347   1.022 (0.992--1.053)
    Increased                                                  36 (6.8%)                6 (9.8%)           2.027     0.363   0.926 (0.598--1.433)
    Normal                                                    264 (49.9%)              25 (41.0%)                           
    Decreased                                                 229 (43.3%)              30 (49.2%)                           
   Lymphocyte percentage (normal range 20--50%)           25.20 (16.70--31.98)    18.70 (13.75--28.21)    --2.439    0.015   0.980 (0.957--1.003)
    Increased                                                  21 (4.0%)                2 (3.2%)           8.265     0.016   0.517 (0.315--0.848)
    Normal                                                    324 (61.4%)              27 (43.5%)                           
    Decreased                                                 183 (34.7%)              33 (53.2%)                           
   Neutrophil percentage (normal range 50--70%)           65.90 (56.40--74.50)    71.70 (57.40--81.80)    --2.135    0.033   1.004 (0.989--1.019)
    Increased                                                 199 (38.0%)              33 (52.4%)          5.658     0.059   1.355 (0.909--2.021)
    Normal                                                    253 (48.4%)              21 (33.3%)                           
    Decreased                                                  71 (13.6%)              9 (13.7%)                            

Calculations were computed by removing NA (not applicable) from each analytical cohort. *z*/χ^2^ means either *z* score or χ^2^ statistics.

###### 

Statistics of the univariate logistic regression models for COVID-19 severity (non-severe, severe) as stratified by significant factors identified from the multivariate logistic regression model

  Characteristics[^a^](#tblfn7){ref-type="table-fn"}   beta      SE      Wald    *P*      Odds ratio (95% CI)
  ---------------------------------------------------- --------- ------- ------- ------- ----------------------
  Age (years)                                          0.026     0.008   9.534   0.002    1.026 (1.009--1.043)
  Contact with confirmed cases                         --0.786   0.389   4.088   0.043    0.456 (0.213--0.976)
  Days from illness onset to diagnosis                 0.063     0.031   4.206   0.040    1.065 (1.003--1.132)
  Neutrophil percentage                                0.004     0.007   0.268   0.604    1.004 (0.989--1.019)
  Lymphocyte percentage                                --0.660   0.253   6.818   0.009    0.517 (0.315--0.848)

Except for 'Contact with confirmed cases', which is categorized as 'Yes' or 'No', all other variables are continuous.

Discussion
==========

The lower mean (43 years) and median (44 years) ages of this cohort, compared with those reported for other regions,[@OP-B3]^,^[@OP-B9]^,^[@OP-B10] were driven by the inclusion of a 6-month old infant; on the other hand, this suggested family transmission. Male patients dominated this case series (male: female ratio = 1.28), which is consistent with other reports.[@OP-B3]^,^[@OP-B4] Hypertension was the most prevalent medical disorder among patients with comorbidities, followed by respiratory diseases and diabetes.

A total of 14 patients were symptom-free, all of whom were \<60 years old and diagnosed within 2 days due to their close contact with infected cases. These patients did not show any symptoms, which might be attributable to the long latency of SARS-CoV-2 and/or the strong immune system of these individuals. Detailed information on the duration from their initial infection source exposure to the diagnosis is required to know whether 'true' symptom-free SARS-CoV-2 carriers exist. Immediate laboratory testing of individuals having close contact with confirmed patients is recommended.

Two of three pregnant patients in this study had severe or terminal disease, which might be associated with their reduced immunity during pregnancy. All eight infected children (aged ≤8 years) were symptom-free, with disease of light or normal severity, suggesting the existence of extended maternal immunity.[@OP-B11]

Of the 671 infected cases, the transmission source of 42 (including 3 medical workers, 1 of whom had hypertension) could be traced back to a hospital and 5 to a wet market, suggesting that these two places are high-risk areas that warrant reduced exposure for the benefits of self-protection and SARS-CoV-2 transmission control.

In this dataset, 33 patients (4.9%) did not visit Wuhan nor have any close contact with confirmed or suspected cases, suggesting the existence of SARS-CoV-2 transmission via fomite, such as aerosol. Among these cases with an unknown transmission source, 21.2% (7) were farmers. This might be due to the high exposure of farmers to the outdoor environment and, possibly, less education and awareness about self-protection against SARS-CoV-2 infection in China. These 33 individuals were abnormally distributed (Shapiro--Wilk statistic = 0.944, *P *=* *5.32 × 10^--15^) by stratifying age into 10-year groups, suggesting that fomite-mediated infection is a random event. The majority of these cases were male (19/33). Except for one male patient with comorbidities in the lung, all patients had light (11) or normal (21) disease severity, suggesting that SARS-CoV-2 transmission via fomite might be less infectious than transmission via living organisms, possibly due to reduced virulence or viability. However, we did not find any statistical significance on this hypothesis.

Among the three conventional pneumonia diagnostic approaches, lymphocyte percentage from routine blood tests on patient admission conveyed prognostic value. It is worth emphasizing that the range of the statistics considered as healthy for each blood test index does not apply for the diagnosis of COVID-19. High lymphocyte percentage was a sign of poor prognosis but was not a good diagnostic measure for COVID-19 due to its large variation.

Typical pneumonia features on CT scans are bilateral ground glass opacities, and CT had a remarkably higher detection rate than X-ray. The false negative rate of CT scans was 2.3%, and that of X-ray was as high as 62%. False negative cases from CT scans all had light or normal disease severity or were symptom-free, and without comorbidities. The distribution of the disease severities of infected individuals not detected on X-ray did not vary from that of the full cohort (χ^2^=1.964, *P *=* *0.161, OR = 1.758, 95% CI: 0.793--3.901) ([Table 4](#dyaa081-T4){ref-type="table"}). This suggests that X-ray was not a feasible approach for COVID-19 diagnosis, and patients without bilateral ground glass opacities on CT scans might not be severely infected.

A longer time from illness onset to diagnosis was associated with higher COVID-19 severity, older age, higher probability of having comorbidities and being male.

Conclusion
==========

This data series is, to our knowledge, by far the largest dataset reported outside Wuhan and at a provincial level in China, which provides information to aid the understanding of COVID-19 clinical manifestation. The main findings include: (i) 'age', 'contact with confirmed cases', 'days from illness onset to diagnosis' and 'lymphocyte percentage' are prognostic of disease severity; (ii) low lymphocyte percentage is associated with severe COVID-19 in general but is not a good index for diagnosis; (iii) X-ray is not a feasible diagnostic approach for COVID-19; (iv) farmers are an occupational group with a high infection rate in Henan province, China; and (v) SARS-CoV-2 transmission via fomite is evident. This study is limited by the missing information in different analytical indexes and lack of follow-up data on the collected cases.
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